

# Reimagining Outcomes in Hemophilia:

Improving Efficacy and Reducing Treatment Burden With High-Sustained Factor and NonFactor Replacement Therapies

## Suggested Readings

### Hemophilia A

Chhabra ES, Liu T, Kulman J, et al. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. *Blood*. 2020;135:1484-1496. doi:10.1182/blood.2019001292

Chowdary P. Inhibition of tissue factor pathway inhibitor (TFPI) as a treatment for haemophilia: rationale with focus on concizumab. *Drugs*. 2018;78:881-890. doi:10.1007/s40265-018-0922-6

Den Uijl IEM, Mauser Bunschoten EP, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? *Haemophilia*. 2011;17:849-853. doi:10.1111/j.1365-2516.2011.02539.x

Eichler H, Angchaisuksiri P, Kavakli K, et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. *J Thromb Haemost*. 2018;16:2184-2195. doi:10.1111/jth.14272

Frei-Jones M, Cepo K, d'Oiron R, et al. Subcutaneous concizumab prophylaxis in patients with hemophilia A or B with inhibitors: efficacy and safety results by hemophilia subtype from the phase 3 explorer7 trial. *Blood*. 2022;140(suppl 1):466-468. doi:10.1182/blood-2022-166522

Jiménez-Yuste V, Angchaisuksiri P, Castaman G, et al. Concizumab prophylaxis in patients with haemophilia A or B with inhibitors: efficacy and safety results from the primary analysis of the phase 3 explorer7 trial. *Res Pract Thromb Haemost*. 2022;6(suppl 1):LB 01.2.

Kenet G, Nolan B, Zulfikar B, et al. A phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis. *Res Prac Throm Haemost*. 2022;6(suppl 1):LB 01.1.

Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. *N Engl J Med*. 2020;383:1018-1027. doi:10.1056/NEJMoa2002699

- Lissitchkov T, Willemze A, Jan C, et al. Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa. *Res Pract Thromb Haemost.* 2023;7:100176. doi:10.1016/j.rpth.2023.100176
- Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. *Blood Adv.* 2022;6:1089-1094. doi:10.1182/bloodadvances.2021006119
- Mahlangu J, Luis Lamas J, Cristobal Morales J, et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results. *Br J Haematol.* 2023;200:240-248. doi:10.1111/bjh.18495
- Malec L, Peyvandi F, Chan AKC, et al. Efanesoctocog alfa prophylaxis for previously treated patients <12 years of age with severe hemophilia A. Presented at: International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress; June 24-28, 2023; Montreal, Canada. Abstract LB01.1.
- Matsushita T, Shapiro A, Abraham A, et al. Phase 3 trial of concizumab in hemophilia with inhibitors. *N Engl J Med.* 2023;389:783-794. doi:10.1056/NEJMoa2216455
- Miesbach W, Klamroth R, Oldenburg J, et al. Gene therapy for hemophilia—opportunities and risks. *Dtsch Arztebl Int.* 2022;119:887-894. doi:10.3238/arztebl.m2022.0353
- Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. *N Engl J Med.* 2022;386:1013-1025. doi:10.1056/NEJMoa2113708
- Pasca S. Concizumab as a subcutaneous prophylactic treatment option for patients with hemophilia A or B: a review of the evidence and patient's perspectives. *J Blood Med.* 2022;13:191-199. doi:10.2147/JBM.S242219
- Pasi KJ, Laffan M, Rangarajan S, et al. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. *Haemophilia.* 2021;27:947-956. doi:10.1111/hae.14391
- Polderdijk SGI, Adams TE, Ivanciu L, et al. Design and characterization of an APC-specific serpin for the treatment of hemophilia. *Blood.* 2017;129:105-113. doi:10.1182/blood-2016-05-718635
- Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. *Nat Med.* 2015;21:492-497. doi:10.1038/nm.3847
- Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. *N Engl J Med.* 2016;374:2044-2053. doi:10.1056/NEJMoa1511769
- Skinner MW, Nugent D, Wilton P, et al. Achieving the unimaginable: health equity in haemophilia. *Haemophilia.* 2020;26:17-24. doi:10.1111/hae.13862
- Srivastava A, Rangarajan S, Kavakli K, et al. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. *Lancet Haematol.* 2023;10:e322-e332. doi:10.1016/S2352-3026(23)00037-6

Tieu P, Chan A, Matino D. Molecular mechanisms of inhibitor development in hemophilia. *Mediterr J Hematol Infect Dis*. 2020;12:e2020001. doi:10.4084/MJHID.2020.001

von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia. *N Engl J Med*. 2023;388:310-318. doi:10.1056/NEJMoa2209226

Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. *Lancet*. 2023;401:1427-1437. doi:10.1016/S0140-6736(23)00284-2

Zhou Z-Y, Hay JW. Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis. *Clin Ther*. 2012;34:434-445. doi:10.1016/j.clinthera.2012.01.001

# Reimagining Outcomes in Hemophilia:

Improving Efficacy and Reducing Treatment Burden With High-Sustained Factor and NonFactor Replacement Therapies

## Suggested Readings

### Hemophilia B

Chowdary P. Inhibition of tissue factor pathway inhibitor (TFPI) as a treatment for haemophilia: rationale with focus on concizumab. *Drugs*. 2018;78:881-890. doi:10.1007/s40265-018-0922-6

Frei-Jones M, Cepo K, d'Oiron R, et al. Subcutaneous concizumab prophylaxis in patients with hemophilia A or B with inhibitors: efficacy and safety results by hemophilia subtype from the phase 3 explorer7 trial. *Blood*. 2022;140(suppl 1):466-468. doi:10.1182/blood-2022-166522

Jiménez-Yuste V, Angchaisuksiri P, Castaman G, et al. Concizumab prophylaxis in patients with haemophilia A or B with inhibitors: efficacy and safety results from the primary analysis of the phase 3 explorer7 trial. *Res Pract Thromb Haemost*. 2022;6(suppl 1):LB 01.2.

Kenet G, Nolan B, Zulfikar B, et al. A phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis. *Res Prac Throm Haemost*. 2022;6(suppl 1):LB 01.1.

Mahlangu J, Luis Lamas J, Cristobal Morales J, et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results. *Br J Haematol*. 2023;200:240-248. doi:10.1111/bjh.18495

Matsushita T, Shapiro A, Abraham A, et al. Phase 3 trial of concizumab in hemophilia with inhibitors. *N Engl J Med*. 2023;389:783-794. doi:10.1056/NEJMoa2216455

Miesbach W, Klamroth R, Oldenburg J, et al. Gene therapy for hemophilia—opportunities and risks. *Dtsch Arztebl Int*. 2022;119:887-894. doi:10.3238/arztebl.m2022.0353

Pasca S. Concizumab as a subcutaneous prophylactic treatment option for patients with hemophilia A or B: a review of the evidence and patient's perspectives. *J Blood Med*. 2022;13:191-199. doi:10.2147/JBM.S242219

Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. *N Engl J Med*. 2023;388:706-718. doi:10.1056/NEJMoa2211644

Polderdijk SGI, Adams TE, Ivanciu L, et al. Design and characterization of an APC-specific serpin for the treatment of hemophilia. *Blood*. 2017;129:105-113. doi:10.1182/blood-2016-05-718635

Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. *Nat Med*. 2015;21:492-497. doi:10.1038/nm.3847

Skinner MW, Nugent D, Wilton P, et al. Achieving the unimaginable: health equity in haemophilia. *Haemophilia*. 2020;26:17-24. doi:10.1111/hae.13862

Srivastava A, Rangarajan S, Kavakli K, et al. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. *Lancet Haematol*. 2023;10:e322-e332. doi:10.1016/S2352-3026(23)00037-6

Tieu P, Chan A, Matino D. Molecular mechanisms of inhibitor development in hemophilia. *Mediterr J Hematol Infect Dis*. 2020;12:e2020001. doi:10.4084/MJHID.2020.001

Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. *Lancet*. 2023;401:1427-1437. doi:10.1016/S0140-6736(23)00284-2

Zhou Z-Y, Hay JW. Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis. *Clin Ther*. 2012;34:434-445. doi:10.1016/j.clinthera.2012.01.001